文献速递眼底病与葡萄膜炎

布西珠单抗治疗新生血管性年龄相关性黄斑变性的安全性结局:IRIS登记研究与Komodo医疗地图的结果

Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map.
PubMed 文献 · JAMA Ophthalmol · 2022-01-01

这项队列研究利用IRIS登记和Komodo医疗地图数据,评估新生血管性年龄相关性黄斑变性患者接受布西珠单抗(Beovu)治疗后眼内炎症(IOI,含视网膜血管炎RV和/或视网膜血管闭塞RO)的真实世界发生率及风险因素。结果显示IOI和/或RO总体发生率约为2.4%,RV和/或RO为0.6%;首次注射前12个月有IOI和/或RO史的患者风险最高(IRIS组8.7%,Komodo组10.6%)。作者指出鉴于研究局限性,所识别的风险因素不能作为IOI和/或RO事件的预测因子,且无法评估与布西珠单抗的因果关系。

要点

  • IOI和/或RO总体发生率约2.4%,RV和/或RO为0.6%。
  • 首次注射前12个月有IOI和/或RO史者风险最高(8.7%和10.6%)。
  • 女性IOI和/或RO发生率高于男性,但风险幅度不及既往IOI和/或RO史。

核心结论

  • IOI和/或RO发生率约为2.4%。
  • 首次布西珠单抗注射前12个月内有IOI和/或RO的患者眼在首次治疗后早期数月内IOI和/或RO观察到的风险率最高。
  • 鉴于研究局限性,所识别的风险因素不能作为IOI和/或RO事件的预测因子,且无法评估与布西珠单抗的因果关系。

研究设计与样本

  • 这是一项队列研究,纳入IRIS登记研究和Komodo医疗地图中2019年10月8日至2020年6月5日期间开始并接受1次或以上布西珠单抗注射、随访至多6个月的新生血管性年龄相关性黄斑变性患者。
  • IRIS组纳入10654只眼,Komodo组纳入11161只眼,中位随访时间分别为97天和95天。
  • 多数眼从其他抗血管内皮生长因子药物转换而来(IRIS组9686/10654[90.9%],Komodo组10487/11161[94.0%]),最常见为阿柏西普(分别为7160/9686[73.9%]和7156/10487[68.2%]),多数为女性(分别为6105/10654[57.3%]和6452/11161[57.8%])。

主要发现

  • IOI和/或RO总体发生率在IRIS组为2.4%(255/10654只眼),在Komodo组为2.4%(268/11161只眼)。
  • RV和/或RO发生率在IRIS组为0.6%(59/10654只眼),在Komodo组为0.6%(63/11161只眼)。
  • 首次布西珠单抗治疗前12个月内有IOI和/或RO史的患者,首次治疗后6个月内IOI和/或RO事件观察到的风险率IRIS组为8.7%(95%CI,6.0%-11.4%),Komodo组为10.6%(95%CI,7.5%-13.7%)。
  • 无既往IOI和/或RO史的患者IOI和/或RO事件观察到的风险率两个数据集均为2.0%。
  • 女性IOI和/或RO估计发生率IRIS组为2.9%(95%CI,2.5%-3.3%),Komodo组为3.0%(95%CI,2.6%-3.4%),男性分别为1.3%(95%CI,1.0%-1.7%)和1.4%(95%CI,1.0%-1.7%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 鉴于研究局限性,所识别的风险因素不能作为IOI和/或RO事件的预测因子。
  • 无法评估与布西珠单抗的因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Limited data exist on the real-world safety outcomes of patients with neovascular age-related macular degeneration treated with brolucizumab (Beovu). OBJECTIVE: To determine the real-world incidence of intraocular inflammation (IOI), including retinal vasculitis (RV) and/or retinal vascular occlusion (RO), for patients with neovascular age-related macular degeneration who underwent brolucizumab treatment. Additionally, potential risk factors associated with these adverse events were evaluated. DESIGN, SETTING, AND PARTICIPANTS: This cohort study included patients with neovascular age-related macular degeneration in the Intelligent Research in Sight (IRIS) Registry and Komodo Healthcare Map. Patients initiating and receiving 1 or more brolucizumab injections from October 8, 2019, to June 5, 2020, with up to 6 months of follow-up were included. INTERVENTION: Brolucizumab injections. MAIN OUTCOME AND MEASURES: Incidence of IOI (including RV) and/or RO and RV and/or RO and risk stratification for the identified risk factors. RESULTS: Of 10 654 and 11 161 included eyes (from the IRIS Registry and Komodo Health database, respectively), the median follow-up times were 97 and 95 days. Most eyes switched from another anti-vascular endothelial growth factor agent (9686 of 10 654 [90.9%] and 10 487 of 11 161 [94.0%], respectively), most commonly aflibercept (7160 of 9686 [73.9%] and 7156 of 10 487 [68.2%]), and most were from women (6105 of 10 654 [57.3%] and 6452 of 11 161 [57.8%]). The overall incidence of IOI and/or RO was 2.4% (255 of 10 654 eyes) and 2.4% (268 of 11 161 eyes) for the IRIS and Komodo groups, respectively, and RV and/or RO, 0.6% (59 of 10 654 eyes and 63 of 11 161 eyes), respectively. Patients with a history of IOI and/or RO in the 12 months before brolucizumab initiation had an increased observed risk rate (8.7% [95% CI, 6.0%-11.4%] and 10.6% [95% CI, 7.5%-13.7%]) for an IOI and/or RO event in the 6 months following the first brolucizumab treatment compared with patients without prior IOI and/or RO (2.0% in both data sets). There was an increased estimated incidence rate in women (2.9% [95% CI, 2.5%-3.3%] and 3.0% [95% CI, 2.6%-3.4%]) compared with men (1.3% [95% CI, 1.0%-1.7%] and 1.4% [95% CI, 1.0%-1.7%]), but this risk was not as large as that of a prior IOI and/or RO. Similar findings were observed for patients with RV and/or RO events. CONCLUSIONS AND RELEVANCE: The incidence rate of IOI and/or RO was approximately 2.4%. Patient eyes with IOI and/or RO in the 12 months prior to first brolucizumab injection had the highest observed risk rate for IOI and/or RO in the early months after the first brolucizumab treatment. However, given study limitations, the identified risk factors cannot be used as predictors of IOI and/or RO events, and causality with brolucizumab cannot be assessed.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Khanani AM, Zarbin MA, Barakat MR, et al. Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map. JAMA Ophthalmol. 2022. PMID: 34817566. doi:10.1001/jamaophthalmol.2021.4585

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。